MedTrace Logo

Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

NCT03384433 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-01-25

No results posted yet for this study

Summary

Administration of cell-free exosomes derived from mesenchymal stem cell (MSCs) can be sufficient to exert therapeutic effects of intact MSCs after brain injury. In this study we aim to assay the administration of MSC derived exosome on improvement of disability of patients with acute ischemic stroke

Conditions

  • Cerebrovascular Disorders

Interventions

BIOLOGICAL

exosome

allogenic mesenchymal stem cells derived exosome enriched by miR-124

Sponsors & Collaborators

  • Tarbiat Modarres University

    collaborator OTHER

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Saeed Oraee-Yazdani, Dr · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-17
Primary Completion
2021-06-17
Completion
2021-12-17

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03384433 on ClinicalTrials.gov